←
Alex Harding3,423 posts
Alex Harding avatar

Alex Harding

@AlexHarding7

An internist in biotech

◷ Joined March 2012▧ 161 Photos and videos
Alex Harding avatar
Alex Harding@AlexHarding7·22h

Maybe stating the obvious, but I think a preclinical biotech raising $5B is a colossal waste of money. Let’s assume their platform is fantastic and will generate a ton of great clinical candidates. You still can’t scale biotech work just by throwing cash at it. If they try to take forward 50 programs in parallel they will make mistakes and get sloppy. This is different than scaling up in AI, where the main constraint and expense is building more computational capacity—a much more readily scalable activity.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round. spr.ly/6010ByTYZ2

Jason Ryan avatar
⟳ Alex Harding retweeted
Jason Ryan@jasonryanmd·Sep 26

Jehovah’s Witnesses can now receive blood transfusions. USMLE question writers in full scale panic. abc.net.au/news/2026-09-24/j…

Dan Diamond avatar
⟳ Alex Harding retweeted
Dan Diamond@ddiamond·Nov 15

After being shot in face by Logan Circle gunman, Susan Hamerski is unable to speak, @conarck reports. “Hamerski’s loved ones asked her to write down on a pad of paper what she wanted to share with the world. She jotted “‘Gun control is public health.’”

One of the victims in Thursday’s shooting rampage in D.C. suffered “serious and severe” wounds while she was walking her daughter’s dog, according to a family friend. wapo.st/48TujRP

Alex Harding avatar
Alex Harding@AlexHarding7·Nov 15

Solid week

This week in medicine 1. FDA approves the first factor XIa inhibitor(!), Bayer's asundexian, for secondary stroke prevention. 2. Australian researchers find that resistance training, alongside tirzepatide, reduces lean mass loss and improves muscle strength versus tirzepatide alone (with no difference in weight loss). 3. Regeneron's liver-targeted CIDEB siRNA, discovered by mining human genetics, reduced liver fat in a first-in-human trial, ~matching retatrutide's unprecedented efficacy. 4. CRISPR Therapeutics' one-time ANGPTL3 gene editor reduced triglycerides and cholesterol, in severe hypertriglyceridaemia, in an early human trial. 5. Beam's one-time base-edited stem cell therapy met its pivotal endpoint in sickle cell disease: FDA submission planned this year. 6. Intellia's in vivo CRISPR therapy for hereditary angioedema maintained suppression of plasma kallikrein for up to four years after a single infusion (with fewer attacks than with patients' previous prophylaxis). 7. Allogene's off-the-shelf CD19×CD70 CAR-T therapy produced responses in patients with systemic sclerosis, including without lymphodepleting chemotherapy, in an early phase 1 trial. 8. Vir's combination of an siRNA (elebsiran) and antibody (tobevibart) eradicated hepatitis D RNA in ~80% of patients, in a phase 3 trial. 9. Beeline's oral TLR7/8 inhibitor achieved clinical responses in systemic lupus erythematosus in a phase 2 trial (a new approach in lupus). 10. Lilly's oral GLP1, orforglipron, improved obstructive sleep apnoea in two phase 3 trials.

Alex Harding avatar
Alex Harding@AlexHarding7·Nov 11

These comments undermine his credibility. I am a big believer in the potential for AI in our industry, but Dario is either extremely naive or cynically hyping his company going into an IPO. The false hope comments like these give to patients does real damage.

“Cancer, Alzheimer’s, heart disease, mental illness - these will be relics of the past in, I think, less than a decade.” — Anthropic CEO @DarioAmodei What do you think, bio folks? Source: instagram.com/reel/DfkundEE2…

Eric Topol avatar
⟳ Alex Harding retweeted
Eric Topol@EricTopol·Nov 10

Setting an unattainable objective. I wish it would come true, but curing all these diseases in the next 10 years is impossible. And I'm very optimistic about the impact of AI for improving health.

NIK@ns123abcNov 10

Anthropic CEO predicts cancer, Alzheimer's, heart disease, mental illness will be cured in less than 10 years ACCELERATE

1:04
deathTouch avatar
⟳ Alex Harding retweeted
deathTouch@deathtouch2k·Nov 10

$ANT $XBI @gline @DaveARicks @DarioAmodei @LifeSciVC @EricTopol @ldtimmerman @adamfeuerstein If you're raising money on the promise that all diseases will be “relics of the past” in ten years, you owe patients and investors an explanation of how you're going to prove it in humans. For context, I'm the founder/CIO of an institutional biotech investment fund that natively integrated AI into its investment process. I've been using information management technology since 2018 to do so. I also went to medical school and used to work on care teams to treat patients in my past life. I had to be in the room, sometimes the one to break the news, when we had to tell kids they wouldn't live to their next birthday, with nothing left in our toolbox to help them or their devastated family. I know what it's like to feel helpless and wishing we could bring therapies to market faster -- that's one of the main reasons I went into the investing side of the business, to effect change at scale. I've reflected on this a lot, so let me try to explain what that promise asks you to believe. I'm not the only person here who has been pushing back on these promises, and I tagged some others who I have found offer great perspectives on this issue too. I'm becoming increasingly upset at the degree to which I'm seeing these AI companies market hopes and dreams to the world, now turning to some of the most desperate and vulnerable in our society to do so. There could be many reasons to own $ANT, but please read this if your only/main reason for buying is on the basis of thinking they can cure all disease in 10 years. This is also entering a level that I consider cruel. Patients who have debilitating or otherwise fatal diseases may be convinced to pour money into these efforts on the basis that they think doing so will lead them to an outcome that is being marketed as an almost certainty that will be substantially different than traditional drug development, thereby potentially reallocating effort and resources away from therapies that today have high promise. This is feeding on the hope of patients who have limited options currently available to them. Let's assume, literally by 4 pm today, we develop a molecule that cures every disease known to man ever and all of this activity is fully funded already. Obviously this is farcical beyond imagination, but bear with me. To sell a new drug in the US, you need FDA approval. That requires evidence that it works and that its benefits outweigh its risks. Before testing it in people, you need to manufacture the drug and generate enough safety data to begin human trials. Let's assume that takes a year. That's an assumption for this example, not a measured average or a minimum. Then you have to test it in humans. Let's assume, again, that our molecule really does cure every disease and has no meaningful side effects. Even then, you still have to generate the evidence. Here are the historical averages for successfully advancing through the three clinical stages: Phase 1: Establish safety and dosing. Average: 2.3 years. Phase 2: Test whether it works in patients and refine the dose. Average: 3.6 years. Phase 3: Confirm the benefit and better establish the risks in larger studies. Average: 3.3 years. These are development-stage averages, including time between studies and stages, from the BIO/Informa/QLS analysis covering 2011 through 2020. go.bio.org/rs/490-EHZ-999/im… For some diseases, the outcomes themselves take years to observe. This is frustrating for everyone: patients, doctors, and investors. I know from each of these perspectives: my own grandfather passed away from complications related to Alzheimer's. In people with Alzheimer’s-related brain changes who have not yet developed symptoms, AHEAD A4 measures cognitive change over approximately 4.2 years. A4 studied cognition over approximately 4.6 years. These aren't minimums, but they show what researchers are trying to establish: whether patients retain their cognitive abilities over time. clinicaltrials.gov/study/NCT…; nejm.org/doi/full/10.1056/NE… FDA can sometimes approve a drug earlier based on a laboratory or imaging measurement reasonably likely to predict benefit. Let's assume that happens wherever possible. But a suitable measurement does not exist for every situation. Accelerated approval still requires studies to confirm that patients actually benefit, although that confirmation can come after the drug reaches patients. fda.gov/drugs/nda-and-bla-ap… Now assume AI lets you prepare and submit the application immediately, FDA has enough resources to give every qualifying application priority review, and everything gets approved on schedule. For a new molecular entity, the ordinary priority review target is approximately eight months after submission: a 60-day filing period plus six months of review. FDA can approve earlier; this is a target, not a minimum (govinfo.gov/content/pkg/CREC…) So add it up: 1 year upfront + 2.3 years in Phase 1 + 3.6 years in Phase 2 + 3.3 years in Phase 3 + 8 months for FDA review = approximately 10 years and 10 months. Again, not the fastest possible timeline, but faster approvals for SOME drugs do not establish that every disease will become a "relic of the past". We started by assuming we already had the molecule TODAY, it cured EVERY disease, had no meaningful side effects, and everything was fully funded. I think I'm being quite generous here on the assumptions side. The actual claim requires discovering those treatments, generating the evidence across all those diseases, getting them approved, manufacturing them, and getting them to patients within the same ten years. Where is the evidence that they can deliver all of that within ten years? If you want to play in the biotech world, you better get used to the idea of providing evidence to back up all your claims. That's the gold standard that protects the US population from harm that would otherwise come at the expense of profits. I'm not arguing AI can't accelerate drug development as we use it in our investment process to great effect. I'm arguing that claiming all diseases will be “relics of the past” in ten years is not supported by these data. Getting a treatment approved is also not the same thing as demonstrating a lasting cure. Selling medical certainty you cannot substantiate exploits the hope of patients who may not live long enough to hold you accountable.

Dario Amodei says cancer, Alzheimer’s, heart disease, and mental illness will be relics of the past in less than a decade, and that "we can create an age of miracles" “You know, if today we look at things like cancer, Alzheimer’s, heart disease, mental illness, these will be relics of the past in, I think, less than a decade." "And I believe that the company which gets the risks right will also be the company that has the license to operate that society trusts and society believes can build the benefits in the right way." "I think if we do this right, we can create an age of miracles where humanity is able to solve problems that have eluded us for millennia." "We have to make sure that all the risks, all the ways that things can go wrong with this technology, we very carefully address those risks as we bring the benefits, and as we have a viable business at the same time.”

0:55
Scott Gottlieb, MD 🇺🇸 avatar
⟳ Alex Harding retweeted
Scott Gottlieb, MD 🇺🇸@ScottGottliebMD·Nov 6

We're reporting only a fraction of measles cases in the US; some estimates put it as low as 20% in states like PA. This outbreak is much larger than what's reported and is spilling into highly vulnerable communities like babies and pregnant women. We will lose our Measles elimination status this month, and it will take years of responsible public health management to get it back. bloomberg.com/news/articles/…

Alex Harding avatar
Alex Harding@AlexHarding7·Nov 1

The beauty of siRNA and selecting targets with human genetic validation in one slide.

The most remarkable thing about Alnylam is how it turned breakthrough science into an engineered platform into a predictable machine for new medicines This chart showing Alnylam’s “probability of success by phase” remains my favorite chart in biotech:

Post attachment
Alex Harding avatar
Alex Harding@AlexHarding7·Oct 31

Just pre-ordered my copy of @JMaraganore's book about building @Alnylam. I'm sure there will a ton of entertaining stories and great lessons for biotech company builders! amazon.com/Importance-Being-… cc @Prof_Oak_

Jason Rhodes avatar
⟳ Alex Harding retweeted
Jason Rhodes@JasonPaulRhodes·Oct 31

On Mithril, AI, biotech venture capital...a few (more) thoughts. First, big congratulations again to Cody @Prof_Oak_, who's terrific and keeps hitting it out of the park. He's been a vital colleague at @atlasventure And big congratulations to @AnthropicAI on the acquisition and bringing Cody on board. Mithril is a story about an intriguing new pharmacologic mechanism, a virtual team with deep disease biology expertise and killer track records in new therapeutic modalities, and AI for operational efficiency. If I had to reduce the secret of success to one thing, in biotech and in life more broadly, it would be to surround yourself with great, great people. Great biotechs pull the right people together for a common purpose, whether employees, consultants, advisors, or at CROs. Our companies have all of them along with all of the people and resources at Atlas that lean in, push, pull, sweat, and strive to build them. Capital intensity and speed are critical issues in biotech. Anything that reduces the first and increase the latter with rigor is a good thing, including the clever application of AI to orchestrate teams of remarkable, real people.

Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All

Alex Harding avatar
Alex Harding@AlexHarding7·Oct 29

New drug candidate for deadly rare neurodegenerative disorder on hold at FDA for obscure/hypothetical tox concern… …meanwhile, absolutely mix together six random peptides and see what happens!

Alex Harding avatar
Alex Harding@AlexHarding7·Oct 28

Congratulations Cody! So cool to see how this has worked out—can’t say that I saw this outcome when you first introduced me to Mithril in fall of 2024!! I’m looking forward to seeing your very cool Mithril program continue forward. It’s a hypothesis that deserves to be tested in the clinic. I’m also very glad to hear you’ll continue posting here as well.

Surprise 1: Anthropic acquired a one-person biotech . . . Surprise 2: that person is me Surprise 3: I’m here to tell you all about it Yes, this is what you think it is; after 6 yrs of increasingly loose anonymity: the Professor Oak reveal post …and yes, it has gotten so boring around here that I’m literally doxxing myself to spice up the timeline ------- Ok, allow me to introduce myself. My name is Cody Tranbarger. I mostly tweet, but occasionally find time to dabble in drug dev & starting/building biotechs. My past lives span the VC, crossover, startup continuum; Prof Oak has been my way of keeping a digital foot in those worlds, despite having my physical feet planted elsewhere. The past 18 mo, ‘elsewhere’ was Mithril Medicine, a co. I founded to develop bsAbs for LAMA2-CMD & other ECM-related genetic diseases. Mithril was born out of hands-on building with @MikeNGladstone, @JasonPaulRhodes, @LifeSciVC, & team @atlasventure. Somehow, I made enough half-decent calls along the way (even a broken clock is right twice a day, eh?) to convince them Mithril/I warranted a small seed. While I can hardly rationalize such an outrageously cavalier bet, I’m grateful for it, & I'd partner with Atlas again in a heartbeat. In typical AV fashion, Mithril’s primordial form was virtual, decentralized, & ultra-lean. This stage tends to be short-lived, but for Mithril, it worked surprisingly well, for surprisingly long, thanks in part to the rapid maturation of the AI tools I used liberally. Eventually, Mithril became a bit of an experiment itself - to find the upper bound of how far it could scale as a single operator + a bunch of Claude (+ a stellar bench of part-time consultants). In parallel, I started spending time with @nc_frey, @an1lam, & @CoefficientBio team; and promptly experienced, for the 1st time, AI at the frontier. Soon thereafter, Mithril stopped looking like an experiment, & started looking like a preview of an entirely new operating model. From that spark came “Pipeline-in-a-Person.” The idea immediately resonated when we shared it here back in April; and it was central to the shared vision that led to Anthropic’s acquisition of Mithril, & my joining the team. Why join Anthropic? Three reasons. (1) For Mithril, the programs continue, with more resources & infrastructure behind them, and as much Claude as I can put to work. (2) For me, the chance to start several more programs, & find out how many one person can actually run in parallel - an almost unprecedented luxury for a curious drug hunter. (3) For our mission, a path to institutionalize & scale this new way of working, then put it in the hands of all of biopharma, all over the world - which, candidly, I find the most energizing. Will AI x Bio cure diseases? Unequivocally yes, imo… but not by the route that gets the most airtime. Rather than timeline acceleration & compression, I see orchestration & parallelization as today's low-hanging fruit. Most drug hunters see a handful of go/no-go calls in a career, & spend entirely too much of the rest trading emails (my inbox can attest). Give them the bandwidth to run several programs at once, and the time to focus on scientific judgment, and I’m willing to bet they’ll make better calls. And at scale, better calls translate to more drugs, higher hit rates, broader patient impact, & likely, a disease or 10 or 100 cured. I couldn't be more excited to build toward that future @AnthropicAI. Finally, a heartfelt thank you to BioTwitter/X. The end of anonymity is bittersweet, but if anyone’s earned a proper introduction, you all have. It’s difficult to overstate how much this app has done for me: a decade of education, plenty of friends, many job opportunities, several mentors, a few investors, even a co-founder (fmr). It was the generosity of this community that inspired me to start posting 6 years ago, after just as many years lurking. I hope I’ve been able to pay it forward, in my own small way. But, to be clear, Prof Oak isn’t going anywhere. Same beat, same themes, and now, a front-row seat to drug development at the frontier. Stay tuned for dispatches from the trenches; and remember... Gotta Cure 'Em All